Cargando…
Advances in adoptive cellular therapy for colorectal cancer: a narrative review
BACKGROUND AND OBJECTIVE: In recent years, adoptive cell therapy (ACT) has shown great potential in antitumor treatment. To significantly improve the clinical efficacy of ACT against solid tumors, we may need to carefully study the latest developments in ACT. As one of the most common malignancies,...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843349/ https://www.ncbi.nlm.nih.gov/pubmed/36660664 http://dx.doi.org/10.21037/atm-22-6196 |
_version_ | 1784870376516354048 |
---|---|
author | Yi, Xing Hu, Wenwei |
author_facet | Yi, Xing Hu, Wenwei |
author_sort | Yi, Xing |
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: In recent years, adoptive cell therapy (ACT) has shown great potential in antitumor treatment. To significantly improve the clinical efficacy of ACT against solid tumors, we may need to carefully study the latest developments in ACT. As one of the most common malignancies, colorectal cancer (CRC) is a major risk to human health and has become a significant burden on global healthcare systems. This article reviews the recent advances in the treatment of CRC with ACT. METHODS: We searched PubMed for articles related to ACT for CRC published as of August 31, 2022, and retrieved relevant clinical trial information on the National Institutes of Health ClinicalTrials.gov website. Based on search results, comprehensive and systematic review is made. KEY CONTENT AND FINDINGS: This article provides an overview of the research progress of ACT for CRC, including chimeric antigen receptor (CAR) T-cell therapy, T-cell receptor (TCR)-engineered T-cell therapy, and tumor-infiltrating lymphocyte (TIL) therapy. Common tumor-associated antigens (TAAs) in clinical trials of CAR-T cell therapy for CRC are described. CONCLUSIONS: Despite many obstacles, ACT shows great promise in treating CRC. Therefore, more basic experimental studies and clinical trials are warranted to further clarify the effectiveness and safety of ACT. |
format | Online Article Text |
id | pubmed-9843349 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-98433492023-01-18 Advances in adoptive cellular therapy for colorectal cancer: a narrative review Yi, Xing Hu, Wenwei Ann Transl Med Review Article BACKGROUND AND OBJECTIVE: In recent years, adoptive cell therapy (ACT) has shown great potential in antitumor treatment. To significantly improve the clinical efficacy of ACT against solid tumors, we may need to carefully study the latest developments in ACT. As one of the most common malignancies, colorectal cancer (CRC) is a major risk to human health and has become a significant burden on global healthcare systems. This article reviews the recent advances in the treatment of CRC with ACT. METHODS: We searched PubMed for articles related to ACT for CRC published as of August 31, 2022, and retrieved relevant clinical trial information on the National Institutes of Health ClinicalTrials.gov website. Based on search results, comprehensive and systematic review is made. KEY CONTENT AND FINDINGS: This article provides an overview of the research progress of ACT for CRC, including chimeric antigen receptor (CAR) T-cell therapy, T-cell receptor (TCR)-engineered T-cell therapy, and tumor-infiltrating lymphocyte (TIL) therapy. Common tumor-associated antigens (TAAs) in clinical trials of CAR-T cell therapy for CRC are described. CONCLUSIONS: Despite many obstacles, ACT shows great promise in treating CRC. Therefore, more basic experimental studies and clinical trials are warranted to further clarify the effectiveness and safety of ACT. AME Publishing Company 2022-12 /pmc/articles/PMC9843349/ /pubmed/36660664 http://dx.doi.org/10.21037/atm-22-6196 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Review Article Yi, Xing Hu, Wenwei Advances in adoptive cellular therapy for colorectal cancer: a narrative review |
title | Advances in adoptive cellular therapy for colorectal cancer: a narrative review |
title_full | Advances in adoptive cellular therapy for colorectal cancer: a narrative review |
title_fullStr | Advances in adoptive cellular therapy for colorectal cancer: a narrative review |
title_full_unstemmed | Advances in adoptive cellular therapy for colorectal cancer: a narrative review |
title_short | Advances in adoptive cellular therapy for colorectal cancer: a narrative review |
title_sort | advances in adoptive cellular therapy for colorectal cancer: a narrative review |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843349/ https://www.ncbi.nlm.nih.gov/pubmed/36660664 http://dx.doi.org/10.21037/atm-22-6196 |
work_keys_str_mv | AT yixing advancesinadoptivecellulartherapyforcolorectalcanceranarrativereview AT huwenwei advancesinadoptivecellulartherapyforcolorectalcanceranarrativereview |